Laboratory of Molecular Biology
Head, Solid Tumor Immunotherapy Section
Principal Investigator

National Cancer Institute
10 Center Drive
Building 37, Room 5116
Bethesda, MD 20892

Dr. Hassan is a medical oncologist and senior investigator at the National Cancer Institute (NCI). Dr. Hassan has focused on developing novel therapies for the treatment of malignant mesothelioma. He is currently conducting clinical trials of two different immunotherapy agents targeting the tumor antigen mesothelin, which was discovered at NCI. Dr. Hassan is the chairman of the Science Advisory Board of the Meso Foundation. He is a recipient of the American Society of Clinical Oncology Career Development Award as well as the National Institutes of Health K23 Career Development Award.

Dr. Hassan's Clinical Trial(s):

NCI’s Center for Cancer Research (CCR) is currently conducting the following trial(s) for patients with malignant mesothelioma, lung cancer, pancreatic cancer, ovarian cancer, or solid tumors. Click on the trial(s) below for additional details, including a summary of key eligibility criteria, study outline, and information on how to contact Dr. Hassan and his staff directly.

A Phase IB Study to Evaluate the Safety and Induction of Immune Response of CRS-207 in Combination With Pemetrexed and Cisplatin as Front-line Therapy in Adults with Malignant Pleural Mesothelioma NCI-12-C-0170, NCT01675765

An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose of the Anti-mesothelin Antibody Drug Conjugate BAY94-9343 in Subjects With Advanced Solid Tumors NCI-12-C-0008, NCT01439152

A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers NCI-11-C-0212, NCT01413451

A Pilot Study of Pentostatin Plus Cyclophosphamide Immune Depletion to Decrease Immunogenicity of SS1P in Patients With Mesothelioma NCI-11-C-0160, NCT01362790